Amicus Therapeutics, Inc. (FOLD)

13.15
NASDAQ
Prev Close 13.29
Day Low/High 12.94 / 13.37
52 Wk Low/High 8.27 / 17.62
Exchange NASDAQ
Shares Outstanding 230.38B
Market Cap 3.06B
Div & Yield N.A. (N.A)
Amicus Therapeutics Looks Impressive If it Can Rally Above $18

Amicus Therapeutics Looks Impressive If it Can Rally Above $18

The combination of three charts gives me a bullish view on FOLD.

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Jim Cramer says investors need to consider the bear the motivation, and they need to consider the big sellers they'll have to outrun.

FedEx, Funko, Amicus Therapeutics: 'Mad Money' Lightning Round

FedEx, Funko, Amicus Therapeutics: 'Mad Money' Lightning Round

Jim Cramer takes a look at FedEx, Funko, Amicus Therapeutics, Turning Point Brands, Sirius XM Radio, and more.

2 Small-Cap Stocks That Are Still a Bargain

2 Small-Cap Stocks That Are Still a Bargain

Despite the January rally, this biotech name and building materials firm still have further to rise.

Interesting FOLD Put And Call Options For February 2019

Interesting FOLD Put And Call Options For February 2019

Investors in Amicus Therapeutics Inc saw new options become available this week, for the February 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new February 2019 contracts and identified one put and one call contract of particular interest.

The Game Plan: Cramer's 'Mad Money' Recap (Friday 9/28/18)

The Game Plan: Cramer's 'Mad Money' Recap (Friday 9/28/18)

Jim Cramer looks ahead to the fourth quarter and has your game plan for next week.

Groupon, Wix.com, Las Vegas Sands: 'Mad Money' Lightning Round

Groupon, Wix.com, Las Vegas Sands: 'Mad Money' Lightning Round

Jim Cramer takes a look at Groupon, Wix.com, Las Vegas Sands, Paycom Software, Bojangles, FedEx, Amicus Therapeutics, Discovery Communications.

First Week Of January 2021 Options Trading For Amicus Therapeutics (FOLD)

First Week Of January 2021 Options Trading For Amicus Therapeutics (FOLD)

Investors in Amicus Therapeutics Inc saw new options become available this week, for the January 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

Amicus Therapeutics Announces Approval Of Galafold® (Migalastat) For Fabry Disease In Japan

Amicus Therapeutics Announces Approval Of Galafold® (Migalastat) For Fabry Disease In Japan

First Amicus Medicine and First Oral Precision Medicine for Fabry Patients with an Amenable Mutation in Japan

Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives To Change People's Lives Living With Rare Diseases

Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives To Change People's Lives Living With Rare Diseases

Unique Volunteerism, Mentorship, Giving, Global Access and Advocacy Programs Under Long-term Healing Beyond Disease Initiatives

U.S. FDA Files New Drug Application Under Priority Review For Migalastat For Treatment Of Fabry Disease

U.S. FDA Files New Drug Application Under Priority Review For Migalastat For Treatment Of Fabry Disease

Six-Month PDUFA Goal Date is August 13, 2018

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

TheStreet Quant Rating: D- (Sell)